Quarterly Updates5 Nov 2025, 08:57 pm
Syngene International's Q2 Revenue Grows 4% Sequentially, 2% YoY to Rs. 911 Cr; Maintains Annual Guidance
AI Summary
Syngene International Limited announced its financial results for the second quarter and half year of FY26. The company reported a 4% sequential and 2% year-on-year growth in revenue from operations, which stood at Rs. 911 Cr. The company maintained its annual guidance for revenue for FY26. The quarter saw the company winning its first global phase III clinical trial from a U.S.-based biotech company and expanding its biologics facility in Bengaluru with a GMP bioconjugation suite. The company also reported a strong balance sheet and net cash position, providing financial flexibility to invest in key strategic priorities.
Key Highlights
- Revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr
- Company maintains annual guidance for revenue for FY26
- First global phase III clinical trial from a U.S.-based biotech company secured
- Expansion of biologics facility in Bengaluru with a GMP bioconjugation suite
- Strong balance sheet and net cash position providing financial flexibility